Multiple Sclerosis: Advances in Understanding Pathogenesis and Emergence of Oral Treatment Options

Lancet Neurol. 2011 Jan;10(1):4-5. doi: 10.1016/S1474-4422(10)70282-9.

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Administration, Oral
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Anticonvulsants / administration & dosage
  • Humans
  • Immunologic Factors / therapeutic use*
  • Interferon beta-1b
  • Interferon-beta / therapeutic use
  • Lamotrigine
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis* / etiology
  • Multiple Sclerosis* / genetics
  • Natalizumab
  • Triazines / administration & dosage

Substances

  • Adjuvants, Immunologic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Anticonvulsants
  • Immunologic Factors
  • Natalizumab
  • Triazines
  • Interferon beta-1b
  • Interferon-beta
  • Lamotrigine